Evidence map›Paper›PMID 35462859›Full record

ReviewJHEP reports : innovation in hepatology2022

Epigenetics of alcohol-related liver diseases.

Nawras W Habash, Tejasav S Sehrawat, Vijay H Shah, Sheng Cao

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in JHEP reports : innovation in hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Non-coding RNAs in alcohol-associated liver disease.Liver research (Beijing, China) · 2025
    Review
  11. Article
  12. Emerging Roles of High-mobility Group Box-1 in Liver Disease.Journal of clinical and translational hepatology · 2024
    Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Nawras W HabashGastroenterology Research Unit, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN USA.
Tejasav S SehrawatGastroenterology Research Unit, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN USA.
Vijay H ShahGastroenterology Research Unit, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN USA.
Sheng CaoGastroenterology Research Unit, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN USA.
Mayo Clinic in Arizona · US

Funding

Molecular Mechanisms of Portal HypertensionR01DK059615 · NIDDK · MAYO CLINIC ROCHESTER · PI SHAH, VIJAY H. · 2002 to 2023
$6.4M
Molecular Mechanisms of Liver Fibrosis (Diversity Supplement)R37AA021171 · NIAAA · MAYO CLINIC ROCHESTER · PI VIJAY H. SHAH · 2019 to 2026
$3.0M
Molecular Mechanisms of Liver FibrosisR01AA021171 · NIAAA · MAYO CLINIC ROCHESTER · PI SHAH, VIJAY H. · 2012 to 2018
$2.5M
NIAAA NIH HHS R01 AA021171NIAAA NIH HHS R37 AA021171NIDDK NIH HHS R01 DK059615
6 · The paper itself

Abstract

Alcohol-related liver disease (ARLD) is a primary cause of chronic liver disease in the United States. Despite advances in the diagnosis and management of ARLD, it remains a major public health problem associated with significant morbidity and mortality, emphasising the need to adopt novel approaches to the study of ARLD and its complications. Epigenetic changes are increasingly being recognised as contributing to the pathogenesis of multiple disease states. Harnessing the power of innovative technologies for the study of epigenetics (

Indexed as

3C, chromosome conformation capture4C, chromosome conformation capture-on-chipAcetylationAH, alcohol-related hepatitisAlcohol liver diseaseARLD, alcohol-related liver diseaseASH, alcohol-related steatohepatitisATAC, assay for transposase-accessible chromatinBET, bromodomain and extraterminal motifBETi, BET inhibitorBRD, bromodomainCCL2, C-C motif chemokine ligand 2Chromatin architectureComputational biologyCTCF, CCCTC-binding factorCXCL, C-X-C motif chemokine ligandDNA methylationDNMT, DNA methyltransferaseE-P, enhancer-promoterEpidrugsEpigeneticsFKBP5, FK506-binding protein 5HCC, hepatocellular carcinomaHDAC, histone deacetylaseHi-C, chromosome capture followed by high-throughput sequencingHIF1α, hypoxia inducible factor-1αHistonesHMGB1, high-mobility group box protein 1HNF4α, hepatocyte nuclear factor 4αHSC, hepatic stellate cellIL, interleukinlncRNA, long non-coding RNALPS, lipopolysaccharideMALAT1, metastasis-associated lung adenocarcinoma transcript 1MECP2, methyl-CpG binding protein 2miRNA, microRNANAFLD, non-alcohol-related fatty liver diseasePPARG, peroxisome proliferator activated receptor-γSAA, salvianolic acid ASingle cell epigenomeSIRT, sirtuinSREBPs, sterol regulatory element-binding proteinsTAD, topologically associating domainTEAD, TEA domain transcription factorTLR, Toll-like receptorTNF, tumour necrosis factorYAP, Yes-associated protein

Identifiers

PMID35462859
PMCPMC9018389
OpenAlexW4220724250

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.